PURPOSE: The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) has been shown to have promising results in antitumor activity through the degradation of the activated V600E mutant of B-Raf (V600E B-Raf) in cutaneous melanoma cell lines. It has different effects, however, on the wild-type form of B-Raf (WT B-Raf), according to the WT B-Raf activation levels in the tumor cells. Uveal melanoma cells express WT B-Raf and only rarely express V600E B-Raf. This study was conducted to investigate the effects of HSP90 inhibition on uveal melanoma cell lines. METHODS: Human uveal melanoma cell lines were treated with the HSP90 inhibitors 17-AAG and 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17-DMAG). Cell proliferation was assessed by MTT staining, and apoptosis was quantified by flow cytometry. Analysis of the expression of HSP90 and activation of the MEK/ERK downstream signaling of B-Raf was performed by Western blot. Effects of the downregulation of the HSP90 cochaperone, cdc37, on cell proliferation and activation of MEK/ERK was investigated by siRNA strategy. RESULTS: The inhibition of HSP90 downregulated B-Raf, decreased cell proliferation, and reduced activation of MEK/ERK in uveal melanoma cell lines expressing WT B-Raf. HSP90 inhibition also reduced the expression of Akt, but the inhibition of Akt had no effect on cell proliferation, ruling out a role of Akt in the 17-AAG-induced inhibition of cell proliferation. The downregulation of cdc37 did not affect MEK/ERK signaling and cell proliferation, demonstrating that the cochaperone was not required for HSP90-controlled stability of B-Raf. c-Kit was also downregulated after HSP90 inhibition. The combination of 17-DMAG with imatinib mesylate, the inhibitor of c-kit, had synergistic inhibitory effects on cell proliferation in WT B-Raf uveal melanoma cell lines. CONCLUSIONS: These results suggest that targeting HSP90 in tandem with c-Kit inhibition may be a promising therapeutic approach to uveal melanoma.
PURPOSE: The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) has been shown to have promising results in antitumor activity through the degradation of the activated V600E mutant of B-Raf (V600E B-Raf) in cutaneous melanoma cell lines. It has different effects, however, on the wild-type form of B-Raf (WT B-Raf), according to the WT B-Raf activation levels in the tumor cells. Uveal melanoma cells express WT B-Raf and only rarely express V600E B-Raf. This study was conducted to investigate the effects of HSP90 inhibition on uveal melanoma cell lines. METHODS:Humanuveal melanoma cell lines were treated with the HSP90 inhibitors 17-AAG and 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17-DMAG). Cell proliferation was assessed by MTT staining, and apoptosis was quantified by flow cytometry. Analysis of the expression of HSP90 and activation of the MEK/ERK downstream signaling of B-Raf was performed by Western blot. Effects of the downregulation of the HSP90cochaperone, cdc37, on cell proliferation and activation of MEK/ERK was investigated by siRNA strategy. RESULTS: The inhibition of HSP90 downregulated B-Raf, decreased cell proliferation, and reduced activation of MEK/ERK in uveal melanoma cell lines expressing WT B-Raf. HSP90 inhibition also reduced the expression of Akt, but the inhibition of Akt had no effect on cell proliferation, ruling out a role of Akt in the 17-AAG-induced inhibition of cell proliferation. The downregulation of cdc37 did not affect MEK/ERK signaling and cell proliferation, demonstrating that the cochaperone was not required for HSP90-controlled stability of B-Raf. c-Kit was also downregulated after HSP90 inhibition. The combination of 17-DMAG with imatinib mesylate, the inhibitor of c-kit, had synergistic inhibitory effects on cell proliferation in WT B-Raf uveal melanoma cell lines. CONCLUSIONS: These results suggest that targeting HSP90 in tandem with c-Kit inhibition may be a promising therapeutic approach to uveal melanoma.
Authors: Delphine R Boulbes; Stefan T Arold; Gaurav B Chauhan; Korina V Blachno; Nanfu Deng; Wei-Chao Chang; Quanri Jin; Tzu-Hsuan Huang; Jung-Mao Hsu; Samuel W Brady; Chandra Bartholomeusz; John E Ladbury; Steve Stone; Dihua Yu; Mien-Chie Hung; Francisco J Esteva Journal: Mol Oncol Date: 2014-11-11 Impact factor: 6.603
Authors: Timothy J Haggerty; Ian S Dunn; Lenora B Rose; Estelle E Newton; James T Kurnick Journal: Assay Drug Dev Technol Date: 2011-11-15 Impact factor: 1.738
Authors: Samuel K Shimp; Cristen B Chafin; Nicole L Regna; Sarah E Hammond; Molly A Read; David L Caudell; Marissanichole Rylander; Christopher M Reilly Journal: Cell Mol Immunol Date: 2012-04-30 Impact factor: 11.530
Authors: Samuel K Shimp; Carl D Parson; Nicole L Regna; Alicia N Thomas; Cristen B Chafin; Christopher M Reilly; M Nichole Rylander Journal: Inflamm Res Date: 2012-02-12 Impact factor: 4.575
Authors: W Maat; M el Filali; A Dirks-Mulder; G P M Luyten; N A Gruis; L Desjardins; P Boender; M J Jager; P A van der Velden Journal: Br J Cancer Date: 2009-06-30 Impact factor: 7.640
Authors: Chun Hei Antonio Cheung; Huang-Hui Chen; Li-Ting Cheng; Kevin W Lyu; Jagat R Kanwar; Jang-Yang Chang Journal: Mol Cancer Date: 2010-04-15 Impact factor: 27.401